

ASX Announcement

Medibio Limited – 16 March 2023

RESIGNATION OF NON-EXECUTIVE DIRECTOR

Melbourne, Australia and Minneapolis, MN – 16 March 2023: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF), announces the resignation of Dr Matt Mesnik as a Non-Executive Director of the Company. Dr Mesnik has resigned as part of the ongoing restructure to the Company's Board and to utilise Dr Mesnik's skillset and industry contacts in a more meaningful way.

It is anticipated that Dr Mesnik will remain committed to assisting Medibio's growth, in an advisory capacity, as he is passionate about the potential that Medibio has to assist in early detection and intervention in mental wellbeing.

The Board takes this opportunity to thank Dr Mesnik for his time and valuable contribution to the Company throughout his tenure.

ENDS

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Melbourne (Vic) and Minneapolis (MN). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

For Further information:

David Trimboli

Non-Executive Chair

investors@medibio.com.au

+61 3 9692 7222